Clostridium difficile immune globulin - Acambis

Drug Profile

Clostridium difficile immune globulin - Acambis

Alternative Names: CdIG

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator Acambis
  • Class Antibacterials; Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Clostridium infections

Most Recent Events

  • 25 Sep 2008 Acambis has been acquired by sanofi pasteur
  • 19 May 2004 Suspended - Preclinical for Clostridium infections in USA (unspecified route)
  • 30 Jul 2002 Preclinical trials in Clostridium infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top